Juan He1, Yanan Cao1, Tingwei Su1, Yiran Jiang1, Lei Jiang1, Weiwei Zhou1, Cui Zhang1, Weiqing Wang1, Guang Ning1,2. 1. Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Key Laboratory for Endocrine Tumors, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. Laboratory of Endocrinology and Metabolism, Institute of Health Sciences, Shanghai Institutes for Biological Science (SIBS), Chinese Academy of Science (CAS), Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China.
Abstract
OBJECTIVE: Previous studies have investigated the genetic and molecular basis of primary aldosteronism (PA), a common cause of human hypertension, but the effects of microRNAs (miRNAs) on the adrenocortical cell proliferation and aldosterone production are largely obscure. Here, we characterized miRNA expression patterns in the subtypes of PA to gain a better understanding of its pathogenesis. METHODS: miRNA expression was assessed by microarray profiling analysis in aldosterone-producing adenoma (APA), unilateral adrenal hyperplasia (UAH) and normal adrenal cortex tissues. Selected differentially expressed miRNAs were further validated in a validation cohort by qRT-PCR. A gain-of-function approach was used to explore the functional role of the specific miRNA in vitro. RESULTS: Of 31 miRNAs including miR-375, miR-7 and miR-29b were found to be significantly differentially expressed among these three groups. miR-375 was the most downregulated one in adrenal cortex tissues from PA patients, and its expression level was inversely correlated with the tumour size in APA. Overexpression of miR-375 in a human adrenocortical cell line (H295R) reduced cell proliferation and suppressed the expression of MTDH (metadherin, also known as astrocyte elevated gene-1). Moreover, MTDH was verified as a direct target of miR-375 through luciferase reporter assays. Knock-down of MTDH in H295R cells attenuated Akt-Ser473 phosphorylation and inhibited cell viability. CONCLUSION: Our findings suggest that miR-375 exerts its tumour-suppressive function via targeting MTDH/Akt pathway and implicate a potential therapeutic target in PA.
OBJECTIVE: Previous studies have investigated the genetic and molecular basis of primary aldosteronism (PA), a common cause of humanhypertension, but the effects of microRNAs (miRNAs) on the adrenocortical cell proliferation and aldosterone production are largely obscure. Here, we characterized miRNA expression patterns in the subtypes of PA to gain a better understanding of its pathogenesis. METHODS: miRNA expression was assessed by microarray profiling analysis in aldosterone-producing adenoma (APA), unilateral adrenal hyperplasia (UAH) and normal adrenal cortex tissues. Selected differentially expressed miRNAs were further validated in a validation cohort by qRT-PCR. A gain-of-function approach was used to explore the functional role of the specific miRNA in vitro. RESULTS: Of 31 miRNAs including miR-375, miR-7 and miR-29b were found to be significantly differentially expressed among these three groups. miR-375 was the most downregulated one in adrenal cortex tissues from PA patients, and its expression level was inversely correlated with the tumour size in APA. Overexpression of miR-375 in a humanadrenocortical cell line (H295R) reduced cell proliferation and suppressed the expression of MTDH (metadherin, also known as astrocyte elevated gene-1). Moreover, MTDH was verified as a direct target of miR-375 through luciferase reporter assays. Knock-down of MTDH in H295R cells attenuated Akt-Ser473 phosphorylation and inhibited cell viability. CONCLUSION: Our findings suggest that miR-375 exerts its tumour-suppressive function via targeting MTDH/Akt pathway and implicate a potential therapeutic target in PA.
Authors: Abel Decmann; Gábor Nyírö; Ottó Darvasi; Péter Turai; Irina Bancos; Ravinder Jeet Kaur; Raffaele Pezzani; Maurizio Iacobone; Ivana Kraljevic; Darko Kastelan; Mirko Parasiliti-Caprino; Mauro Maccario; Nina Nirschl; Daniel Heinrich; Martin Reincke; Attila Patócs; Peter Igaz Journal: Front Endocrinol (Lausanne) Date: 2019-10-29 Impact factor: 5.555
Authors: Erika Larrea; Carla Sole; Lorea Manterola; Ibai Goicoechea; María Armesto; María Arestin; María M Caffarel; Angela M Araujo; María Araiz; Marta Fernandez-Mercado; Charles H Lawrie Journal: Int J Mol Sci Date: 2016-04-27 Impact factor: 5.923
Authors: Anthony R Glover; Jing Ting Zhao; Anthony J Gill; Jocelyn Weiss; Nancy Mugridge; Edward Kim; Alex L Feeney; Julian C Ip; Glen Reid; Stephen Clarke; Patsy S H Soon; Bruce G Robinson; Himanshu Brahmbhatt; Jennifer A MacDiarmid; Stan B Sidhu Journal: Oncotarget Date: 2015-11-03